Zoetis enters its third-quarter report as a company that has spent most of 2026 resetting its own expectations. Management has trimmed its outlook repeatedly, and the latest update cut it sharply again. The animal health leader now projects full-year earnings of $6.15 to $6.25 per share on revenue of $9.12 billion to $9.32 billion, down from a prior range of $6.85 to $7.00 on $9.68 billion to $9.96 billion. The question on November 5 is no longer whether the companion animal business has slowed. It is whether this reset finally captures the damage or whether the floor is still moving.

For the September quarter, analysts expect earnings of $1.51 per share on revenue of $2.30 billion, which would be an 11.2% drop in profit and a 4.2% decline in sales from a year earlier, when Zoetis earned $1.70 on $2.40 billion. That is outright contraction, not a pause, and a notable step down from the $1.87 and $2.47 billion posted last quarter. The Earnings Whisper of $1.49 sits a hair below consensus, a small gap that nonetheless hints the informal bar is drifting lower rather than higher. More telling is the full-year picture: consensus of $6.87 per share and $9.72 billion in revenue sits well above management's new range, which suggests many published estimates have not caught up with the latest cut. Expect revisions after the report regardless of the quarterly headline.

The previous call explains why the outlook keeps shrinking. Price realization guidance slid from 2% to 3% at the start of the year, to 1% to 2%, and then to flat or slightly negative, with second-quarter price landing flat after a 2% gain in the first quarter. A new competitor entered the U.S. dermatology market during the second quarter, turning a long-anticipated threat into a real one, and management conceded that share and volume pressure could persist for six to 18 months. Its response was a notable shift in posture: leaning into rebates, promotions and point-of-sale discounts to protect volume, after years of insisting Zoetis competes on differentiation rather than price. This quarter offers the first full look at how that strategy performs. Validation would be dermatology volumes that hold up reasonably well against the new entrant with net pricing erosion contained. A challenge would be deeper negative price paired with continued share loss, meaning Zoetis is paying more and still losing ground. Softer U.S. vet traffic, with wellness and heartworm visits down roughly 7%, and continued weakness in osteoarthritis pain products such as Librela also need to stabilize.

The offsets matter too. Livestock was the standout last quarter, rising 11% globally and 23% in the U.S., helped by supply timing and New World Screwworm demand for injectable parasiticides. Management guided to mid-to-high single digit growth for the year, so a sharp slowdown here would remove a key cushion. Cost discipline, including a 4% decline in SG&A and lower manufacturing costs, should help margins absorb heavier gross-to-net spending. Any update on U.S. approval of long-acting Cytopoint, still expected this year, would offer a rare product-driven bright spot in dermatology.

Sentiment has softened from 67.4% bearish before last quarter to 53.4% bearish now, still negative but less lopsided. The stock has roughly tracked the market since the last report, slipping 0.8% against a 0.1% dip in the S&P 500, and at $78.23 trades far below its 200-day average of $94.39, in the upper half of its post-earnings range of $68.77 to $82.29. Ultimately, the report hinges on whether Zoetis can show that its dermatology franchise is holding share at an acceptable price. If it can, the latest reset may mark a bottom; if not, investors will question whether this guidance is the last cut.